February 2026 Research Update

What this month clarified

Across this month’s reports, most people with immune TTP (iTTP) given caplacizumab had platelet recovery quickly, and situations that looked like the drug was not working were usually explained by other problems happening at the same time. At the same time, safety reports continued to point to bleeding as the main side effect, often showing up early after starting the drug. A separate single case raised a new possibility that very rare genetic differences in von Willebrand factor (a clotting protein) might help explain true resistance in exceptional situations. [1] [2] [3]

In routine-care registry data covering 204 acute iTTP episodes, clinical response by day 5 was common, and the small number of cases meeting laboratory definitions of refractoriness had plausible alternative explanations. When platelet counts stayed low longer than expected, the key factor linked to delay was having another cause of low platelets, rather than baseline TTP features. This helps frame delayed platelet recovery as a signal to look for competing explanations, not automatically as proof that iTTP is uncontrolled under caplacizumab. [1]

Post-marketing safety reports for caplacizumab most strongly flagged bleeding-related events, with a typical onset around the first couple of weeks and a pattern suggesting many events cluster early. Because these are voluntary reports and not a controlled comparison, they cannot show how often bleeding happens or prove the drug caused each event. Still, they reinforce bleeding as the main safety issue being seen in real-world reporting. [2]

One case report described what the authors considered the first documented caplacizumab resistance in iTTP, tied to a specific change in the von Willebrand factor A1 region (P1266L). In that patient, laboratory testing suggested the drug did not suppress von Willebrand factor activity as expected and platelet capture persisted in a flow-based test. This is an early, single-patient signal that unusual biology might rarely change how caplacizumab behaves, but it does not show how often this occurs. [3]

What this may mean for patients and caregivers

For people treated with caplacizumab for iTTP, this month adds reassurance that true lack of response appears uncommon in registry experience, and that other medical issues can be an important reason platelet counts recover slowly. The safety signal that stands out most is bleeding, especially early after starting therapy, based on post-marketing reports. The resistance case is mainly a research-level finding right now, pointing to a possible explanation for very rare exceptions rather than a common concern. What remains uncertain is how often genetic differences in von Willebrand factor contribute to unusual responses, and how best to identify those cases. [1] [2] [3]

What this month clarified

This month emphasized that TTP sits within a larger group of look-alike conditions, and that getting the label right matters because the causes and expected course can differ. Large hospital data suggested outcomes were not worse for weekend admissions, but were worse when treatment was started later and in smaller hospitals. Several individual reports highlighted common real-world dilemmas, such as early test results being misleading and non-TTP causes (like malignant hypertension) initially appearing similar to TTP. [4] [5] [6]

In a US hospital database study (2016 to 2019), in-hospital mortality for TTP admissions was 6.2%. After accounting for other factors, weekend versus weekday admission did not show a mortality difference, while smaller hospital size and a longer delay to starting therapeutic plasma exchange were linked with more deaths. For patients and families, this frames timing of key hospital treatment and hospital resources as measurable factors connected to outcomes in real-world data. [4]

A case of malignant hypertension-related thrombotic microangiopathy (a TTP-like clotting problem) showed how an intermediate-risk score and early low platelets can lead to initial TTP-directed treatment, even when the underlying cause is different. Platelets improved after plasma exchange, but ongoing blood cell breakdown improved only after blood pressure control, and later ADAMTS13 testing supported that this was not TTP. The main message is that repeated reassessment, including follow-up testing, can clarify the true cause when the clinical picture evolves. [5]

Another case report described iTTP where ADAMTS13 activity was very low but the initial inhibitor test was negative, and repeating inhibitor testing helped support the working diagnosis while treatment continued. This highlights that a single negative inhibitor result may not always settle the question early in the illness. For patients, it explains why teams may repeat blood tests when the first results do not fully match the overall clinical picture. [6]

A commentary on a separate reported case questioned whether heart dysfunction in iTTP should be labeled as myocarditis versus small-vessel blood flow problems caused by TTP itself. The authors argued that without stronger diagnostic evidence, microvascular ischemia could be a more fitting explanation, and that the distinction could matter for understanding the illness course. This does not add new patient data, but it underlines that organ symptoms in TTP can have more than one explanation. [7]

What this may mean for patients and caregivers

This set of studies mainly adds understanding rather than changing what patients should do. It explains why TTP diagnosis and monitoring can involve repeated testing and revisiting earlier assumptions, because some TTP-like conditions improve only when the underlying trigger is treated, and early antibody testing can sometimes be negative. The hospital outcomes study may matter now in a practical sense by showing that system factors like time to plasma exchange and hospital size were linked with survival, while weekend admission itself was not. What remains uncertain is how often specific organ problems (like heart dysfunction) represent one mechanism versus another in iTTP, because that debate is still based on limited individual cases and interpretation. [4] [5] [6] [7]

What this month clarified

This month expanded the picture beyond classic immune TTP by highlighting several different pathways that can lead to TTP or TTP-like clotting problems. A broad genetics review reinforced that inherited factors matter for both immune and congenital TTP, while case-based papers showed how medications and autoimmune disease can be involved in TTP presentations. Separate pharmacovigilance work in cancer therapy emphasized that some anti-VEGF drugs are linked to thrombotic microangiopathy and TTP reports, with supporting laboratory and animal findings proposed as possible mechanisms. [8] [9] [10] [11] [12] [13]

A systematic review of genetics reported that certain HLA types have been repeatedly linked with higher or lower risk of immune TTP across studies, although effect sizes varied by ancestry. For congenital TTP, the review compiled many ADAMTS13 gene changes, with a notable clustering in one part of the gene (exon 7) where 32 variants were described. For families, this reinforces that congenital TTP often has identifiable gene changes, and immune TTP risk can be influenced by inherited immune-system markers, even though genes are not the whole story. [8]

One case report described late-onset congenital TTP confirmed by finding two ADAMTS13 gene variants, with low ADAMTS13 activity and no inhibitor detected. After treatment during the acute episode, the report noted no TTP recurrence and normalized kidney function at 1-year follow-up, while the person received preventive plasma infusions. As a single case, it cannot predict outcomes for others, but it illustrates how congenital TTP can first appear in adulthood and be confirmed with genetic testing. [12]

A separate case report described acquired TTP occurring after one dose of pembrolizumab (a PD-1 immunotherapy drug), with very low ADAMTS13 activity. The patient’s condition worsened and plasma exchange was not performed, and the article also summarized prior published case reports of PD-1 inhibitor-associated acquired TTP. This adds to the documented range of rare immune-related blood complications reported with checkpoint inhibitors, while still relying mainly on individual case evidence. [9]

A case plus literature review looked at secondary thrombotic microangiopathy in the setting of systemic lupus erythematosus and reported platelet improvement after three plasma exchange sessions, with ADAMTS13 activity at 16% and no inhibitor. In the assembled set of published case reports, outcomes after plasma exchange varied by cause, and malignancy-associated cases were described as having the poorest prognosis. Because this evidence is drawn from heterogeneous case reports, it helps map possibilities but cannot give firm, cause-by-cause expectations. [10]

In cancer patients exposed to VEGF or VEGFR pathway inhibitors, pharmacovigilance databases showed stronger reporting signals for thrombotic microangiopathy with VEGF inhibitors than with VEGFR inhibitors, while the reported onset tended to be earlier with VEGFR inhibitors. The same paper added local hospital data and animal and gene-expression work pointing toward reduced VEGF signaling, complement activation, and platelet activation as possible mechanisms. For patients, the clearest message is that some cancer drugs have a recognized link to TTP-like syndromes in safety monitoring, while the mechanism work is still early-stage research. [11]

A letter raised a hypothesis that congenital TTP might be linked with Legg-Calve-Perthes disease (a childhood hip condition related to reduced blood flow) and suggested looking for overlap in registries and testing ADAMTS13 activity in Perthes cohorts. There were no new patient data in this piece, but it highlights how researchers look for patterns that might connect rare clotting conditions with other ischemic diseases. This idea remains unproven and is mainly a prompt for future research. [13]

What this may mean for patients and caregivers

These studies broaden the understanding of why TTP can happen, including inherited causes (congenital TTP), immune-triggered causes (including rare drug-related cases), and TTP-like syndromes related to cancer therapies or autoimmune disease. Most of this theme may matter more for long-term understanding and research than for immediate decisions, because much of the evidence comes from reviews, pharmacovigilance databases, and individual cases. What became clearer is that genetics is central for congenital TTP, and that certain medications are repeatedly reported alongside TTP or TTP-like syndromes in real-world safety data. What remains uncertain is how often these suspected triggers truly cause TTP in an individual person, and which biological pathways are most important in different settings. [8] [12] [9] [10] [11] [13]